Filing Flows › Mimedx Group (MDXG) › Q3 2026 › vs Q2 2026
Mimedx Group (MDXG) Q3 2026 vs Q2 2026 (quarter over quarter)
Mimedx Group's revenue fell $2.1M (-3%) from $64.4M in Q2 2026 to $62.3M in Q3 2026. The biggest changes: Wound −$2.7M (-11%); Surgical +$663K (+2%).
Mimedx Group, Q3 2026: revenue $62.3M (-45% year over year), operating margin -18.8%, net loss $8.7M, operating cash flow $3.9M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Surgical | $40.0M | $39.3M | $663K | +2% |
| Wound | $22.3M | $25.1M | −$2.7M | -11% |
| Revenue | $62.3M | $64.4M | −$2.1M | -3% |
| Other income, net | $640K | $686K | −$46K | -7% |
| Income tax benefit | $2.4M | $2.9M | −$561K | -19% |
| Net loss | $8.7M | $14.8M | −$6.2M | -41% |
| Costs & expenses | $74.0M | $82.8M | −$8.8M | -11% |
| Operating costs | $74.0M | $82.8M | −$8.8M | -11% |
| Cost of revenue | $12.6M | $20.0M | −$7.4M | -37% |
| Research & development | $2.8M | $2.8M | $19K | +0.7% |
| SG&A | $58.3M | $59.8M | −$1.5M | -2% |
| Other operating costs | $295K | $291K | $4K | +1% |
| Operating cash sources | $12.6M | $4.8M | $7.8M | +161% |
| Depreciation & amortization | $665K | $732K | −$67K | -9% |
| Share-based compensation | $3.2M | $903K | $2.3M | +256% |
| Working capital & other | $8.7M | $3.2M | $5.5M | +174% |
| Net loss absorbed | $8.7M | $14.8M | −$6.2M | -41% |
| Operating cash flow | $3.9M | −$10.0M | $13.9M | — |
Questions
How much did Mimedx Group's revenue grow quarter over quarter in Q3 2026?
Mimedx Group's revenue fell $2.1M (-3%) from $64.4M in Q2 2026 to $62.3M in Q3 2026.
What drove Mimedx Group's revenue change in Q3 2026?
Wound −$2.7M (-11%); Surgical +$663K (+2%).